Immunochina Pharmaceuticals is Pharmaceuticals in China that focus on cell therapy business. Founded in 2015. They cover business area such as developer, gene cell medicine technology, malignant tumor treatment, CAR-T technology, immune cell therapy, cancer, immunology, research, practitioner, effective way, hematological malignancy.
2015
( 9 years old in 2024 )
Cell Therapy
-
Building 1, Block B, Yiyuan Cultural and Creative Industry Base
No. 65 Xingshikou Road, Haidian District
Beijing, 100089
China
Private
developergene cell medicine technologymalignant tumor treatmentCAR-T technologyimmune cell therapycancerimmunologyresearchpractitionereffective wayhematological malignancy
* We use standard office opening hours in near Immunochina Pharmaceuticals's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Immunochina Pharmaceuticals is Pharmaceuticals business from China that founded in 2015 (9 years old in 2024), Immunochina Pharmaceuticals business is focusing on Cell Therapy.
Immunochina Pharmaceuticals headquarter office and corporate office address is located in Building 1, Block B, Yiyuan Cultural and Creative Industry Base No. 65 Xingshikou Road, Haidian District Beijing, 100089 China.
Immunochina Pharmaceuticals was founded in China.
In 2024, Immunochina Pharmaceuticals is currently focus on cell therapy sector.
Above is snippet of Google Trends for "cell therapy" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Immunochina Pharmaceuticals, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
